Support By : Li-lab
| PATHWAY_NAME | REACTOME_ID | KEGG_ID | DRUG_NAME | PUBCHEM_CID | Datasource |
|---|---|---|---|---|---|
| Regulation of actin cytoskeleton | R-HSA-392751 | map04810 | moxonidine | 4810 | drug-path |
| MAPK signaling pathway | R-HSA-9652817 | map04010 | moxonidine | 4810 | drug-path |
| Gap junction | R-HSA-190861 | map04540 | moxonidine | 4810 | drug-path |
| Cardiac muscle contraction | R-HSA-397014 | map04260 | moxonidine | 4810 | drug-path |
| Cytokine-cytokine receptor interaction | R-HSA-6788467 | map04060 | moxonidine | 4810 | drug-path |
| GnRH signaling pathway | R-HSA-168638 | map04912 | moxonidine | 4810 | drug-path |
| Long-term depression | R-HSA-9620244 | map04730 | moxonidine | 4810 | drug-path |
| Systemic lupus erythematosus | R-HSA-977105 | map05322 | moxonidine | 4810 | drug-path |
| Phosphatidylinositol signaling system | R-HSA-1280215 | map04070 | terazosin | 5401 | drug-path |
| Olfactory transduction | R-HSA-9751605 | map04740 | terazosin | 5401 | drug-path |
| Fc epsilon RI signaling pathway | R-HSA-2454202 | map04664 | terazosin | 5401 | drug-path |
| Long-term potentiation | R-HSA-9620244 | map04720 | terazosin | 5401 | drug-path |
| Gap junction | R-HSA-190861 | map04540 | terazosin | 5401 | drug-path |
| Parkinson's disease | R-HSA-1643685 | 0 | terazosin | 5401 | drug-path |
| GnRH signaling pathway | R-HSA-168638 | map04912 | terazosin | 5401 | drug-path |
| Long-term depression | R-HSA-9620244 | map04730 | terazosin | 5401 | drug-path |
| Systemic lupus erythematosus | R-HSA-977105 | map05322 | terazosin | 5401 | drug-path |
| Notch signaling pathway | R-HSA-157118 | map04330 | terazosin | 5401 | drug-path |
| Leukocyte transendothelial migration | R-HSA-8950732 | map04670 | cefalonium | 21743 | drug-path |
| Glioma | Q9NZM4 | map05214 | alsterpaullone | 5005498 | drug-path |